757239-40-0

Upstream product

• 757239-39-7 4-(1,2-dihydroxyethyl)-1-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester 
• 757239-38-6 4-[2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl]-piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-ethyl ester 
• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 757239-44-4 (4S)-4-[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxa-bicyclo[2.2.1]heptane-1-carbonyloxy]-2-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid benzyl ester 
• 757239-43-3 (4R)-4-[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxa-bicyclo[2.2.1]heptane-1-carbonyloxy]-2-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Stereoselective synthesis of a potent human NK1 receptor antagonist via acyl-Claisen rearrangement

Stereoselective synthesis of the tetrahydropyran derivative 1 is reported. Diastereoselective acyl-Claisen rearrangement was employed for formation of C3 and C4 chiral centres on the tetrahydropyran ring. Georg Thieme Verlag Stuttgart.

TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS

The present invention relates to the compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and W are as defined herein, and pharmaceutically acceptable salts thereof; the compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.